1.
Clin Infect Dis
; 61(3): 476-9, 2015 Aug 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-25917636
RESUMEN
In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received ≥48 weeks of treatment with extended-release nevirapine. By last visit, all patients had undetectable viral loads and no new safety signals, demonstrating the safety and efficacy of a once-daily antiretroviral regimen.